3 Stocks Pushing The Health Care Sector Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 57 points (-0.3%) at 18,059 as of Friday, June 19, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,336 issues advancing vs. 1,624 declining with 175 unchanged.

The Health Care sector currently sits down 0.2% versus the S&P 500, which is down 0.3%. Top gainers within the sector include HCA Holdings ( HCA), up 1.7%, Bristol-Myers Squibb Company ( BMY), up 1.0%, AbbVie ( ABBV), up 0.9%, Amgen ( AMGN), up 0.8% and CVS Health ( CVS), up 0.6%. On the negative front, top decliners within the sector include Biomarin Pharmaceutical ( BMRN), down 1.5%, Novo Nordisk A/S ( NVO), down 1.3%, Merck ( MRK), down 0.8% and Gilead ( GILD), down 0.6%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. Baxter International ( BAX) is one of the companies pushing the Health Care sector higher today. As of noon trading, Baxter International is up $0.51 (0.7%) to $69.76 on heavy volume. Thus far, 3.1 million shares of Baxter International exchanged hands as compared to its average daily volume of 4.1 million shares. The stock has ranged in price between $69.01-$69.94 after having opened the day at $69.32 as compared to the previous trading day's close of $69.25.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. Baxter International has a market cap of $37.1 billion and is part of the health services industry. Shares are down 7.0% year-to-date as of the close of trading on Thursday. Currently there are 3 analysts who rate Baxter International a buy, 1 analyst rates it a sell, and 9 rate it a hold.

TheStreet Ratings rates Baxter International as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, reasonable valuation levels and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, generally higher debt management risk and weak operating cash flow. Get the full Baxter International Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Express Scripts ( ESRX) is up $0.76 (0.8%) to $90.35 on average volume. Thus far, 3.1 million shares of Express Scripts exchanged hands as compared to its average daily volume of 4.2 million shares. The stock has ranged in price between $89.08-$90.82 after having opened the day at $89.57 as compared to the previous trading day's close of $89.59.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company operates through two segments, PBM and Other Business Operations. Express Scripts has a market cap of $64.2 billion and is part of the health services industry. Shares are up 4.0% year-to-date as of the close of trading on Thursday. Currently there are 12 analysts who rate Express Scripts a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Express Scripts as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full Express Scripts Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Biogen ( BIIB) is up $9.88 (2.5%) to $411.44 on heavy volume. Thus far, 1.5 million shares of Biogen exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $406.61-$413.91 after having opened the day at $406.61 as compared to the previous trading day's close of $401.55.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. Biogen has a market cap of $91.9 billion and is part of the drugs industry. Shares are up 15.2% year-to-date as of the close of trading on Thursday. Currently there are 10 analysts who rate Biogen a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Biogen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Biogen Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

More from Markets

Sprint, T-Mobile Might Have to Do More Than Make Promises to Get Deal Approved

Sprint, T-Mobile Might Have to Do More Than Make Promises to Get Deal Approved

Video: The S&P 500 Is Failing to Make New Highs

Video: The S&P 500 Is Failing to Make New Highs

Dow, S&P 500 and Nasdaq Finish Lower as Apple, P&G Slump

Dow, S&P 500 and Nasdaq Finish Lower as Apple, P&G Slump

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Video: Jim Cramer on Apple, Procter & Gamble, Nucor and Acacia Communications

Video: Jim Cramer on Apple, Procter & Gamble, Nucor and Acacia Communications